Prelude Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Delaware, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
175 Innovation Blvd, Wilmington, Delawar...Phone Number
(302) 467-1280Website
www.preludetx.comRevenue
$16.7 MillionStock Symbol
PRLDIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Prelude Therapeutics
Founded in 2016 and headquartered in Newark, Delaware, Prelude Therapeutics Incorporated operates as a biopharmaceutical company. The Company develops and designs a pipeline of novel, orally bioavailable, and small molecule therapies that target key drivers of cancer cell growth.Explore more
Prelude Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Prelude Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Prelude Therapeutics
Earning: See what the market has to say on Prelude Therapeutics recently announced quarterly report
Product Launch: Get notified when Prelude Therapeutics launches new products
Check if Prelude Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Prelude Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Prelude Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Prelude Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Check out if Prelude Therapeutics is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Prelude Therapeutics
Compare insights from companies similar to Prelude Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$19.7M
11-50
Private
-
1989
RK
Randie KutzenDeputy Executive Director, Operations & Program Director, Iddap
Company Profile Activity
Activity Insights
Prelude Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Prelude Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Prelude Therapeutics.
Prelude Therapeutics financials insights
Gather financial insights about Prelude Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$5M
2019
Series B
$60M
2020
Series C
$50M
Stock Offering
$158M
Prelude Therapeutics Tech Stack
A closer look at the technologies used by Prelude Therapeutics
Most Recent Scoops
Person-Based
Research & Development
Person-Based
Business Finance, Finance, Financing & Debt
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Prelude Therapeutics News & Media
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)Prelude Therapeutics (PRLD) grants CMO 450000 stock options at $4.70
Chief Medical Officer Charles Q. Morris receives 450,000 Prelude Therapeutics stock options at a $4.70 exercise price, vesting over four years with expiration on April 30, 2036.Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer
Prelude Therapeutics (NASDAQ:PRLD) is one of the best biotech penny stocks to buy in 2026. On April 20, Prelude Therapeutics presented promising preclinical data for PRT13722, a first-in-class, oral KAT6A degrader. Designed for HR+/HER2- breast cancer, the candidate demonstrated the ability to achieve complete tumor regressions as a monotherapy across multiple models, including those resistant […]RA Capital reports 7.88M-share Prelude Therapeutics (PRLD) stake - Stock Titan
RA Capital–related entities report 7.88M Prelude Therapeutics Common shares in a new Form 3, held indirectly through RA Capital Healthcare Fund.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Prelude Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2016 and headquartered in Newark, Delaware, Prelude Therapeutics Incorporated operates as a biopharmaceutical company. The Company develops and designs a pipeline of novel, orally bioavailable, and small molecule therapies that target key drivers of cancer cell growth.... Read More
